NCT04095390
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Endocrine (Hormone) Therapy, Serine-Threonine Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic central nervous system metastasis – see trial for details; Patients who have been treated with more than 1 line of systemic therapy in the metastatic setting; Patients who have not previously been treated with Herceptin/trastuzumab; Patients who received HER2 targeting tyrosine kinase inhibitors (e.g. Tukysa/tucatinib, Nerlynx/neratinib, Tykerb/lapatinib); Patients who received any CDK4/6 inhibitor (e.g. Ibrance/palbociclib, abemaciclib/Verzenio, ribociclib/Kisqali); Patients who received Xeloda/capecitabine
https://ClinicalTrials.gov/show/NCT04095390